base metals investing Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
base metals investing Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
base metals investing Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
base metals investing Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting
base metals investing Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
base metals investing Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635
base metals investing Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
base metals investing Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers
Equity Metals Reports Assays from 2026 Validation Drilling on the No. 3 Vein and Active Q4 Exploration Initiatives, Silver Queen Project, BC
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
SAGA Metals Drills 495.6 m at 37.86% Fe2O3, 5.51% TiO2, 0.273% V2O5 Including 68.2 m at 52.95% Fe2O3, 8.57% TiO2, 0.381% V2O5 at Radar Critical Minerals Project in Labrador
